Navigation Links
KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids

NORTH LIBERTY, Iowa, Feb. 14, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, offered its support for the recent Food and Drug Administration (FDA) recommendations to curtail the potential abuse of opioid-based therapeutics. 

In two separate actions, on January 25, 2013, the FDA's Drug Safety and Risk Management Advisory Committee (DSaRM) voted in favor of reclassifying hydrocodone combination products from Schedule III to Schedule II under the Controlled Substances Act, and on January 10, 2013, the FDA issued a draft guidance to assist pharmaceutical companies in the development of abuse-deterrent formulations of opioids.  

Travis C. Mickle , Ph.D., president and CEO of KemPharm, commented, "Opioid-based therapeutics manage pain very well, but safe-guards and technological enhancements are needed to mitigate a clear abuse risk.  The recent FDA actions clearly speak to this issue, and KemPharm welcomes the 'call-to-arms' as we advance the development of our lead compound, KP201 (benzhydrocodone)." 

Mickle continued, "The more stringent hydrocodone classification and the opioid abuse-deterrent development guidelines will undoubtedly serve to focus our industry, but advances in technology will be the ultimate factor in effecting positive change.  This is KemPharm's rationale for developing KP201.
Benzhydrocodone, which is chemically different from hydrocodone, has demonstrated the potential to reduce drug abuse and diversion as well as prevent opioid-induced constipation (OIC), while maintaining the same pain relieving effects of current market leading drugs."

KP201 is in development for the treatment of acute moderate to moderately severe pain with a new drug application (NDA) expected to be filed in Q2 2014.  Recently assigned the nonproprietary name, "benzhydrocodone," by the United States Adopted Name (USAN) Council, KP201 represents the first novel pain therapy of the morphine class to be developed in a number of years with an officially recognized new chemical structure. 

About KP201
KemPharm's most advanced opioid-based drug candidate, KP201, is composed of hydrocodone chemically bound to a ligand.  The Company previously reported positive Phase 1 clinical data, which confirmed that KP201 is metabolized in man as predicted, releasing hydrocodone into the bloodstream at amounts equivalent to the reference listed drug, Norco®.  This data supports a 505(b)(2) regulatory pathway for KP201 in combination with acetaminophen. 

KP201 has unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC).  Importantly, intact KP201 was not detected in systemic circulation, suggesting that minimal additional studies could be justified to determine the impact of KP201 exposure in the body. 

KemPharm has worked diligently with its manufacturing partner, Johnson Matthey , to successfully and efficiently scale up KP201 active pharmaceutical ingredient (API) in anticipation of a commercial launch.  KP201 is on track for an NDA submission to the FDA in 2014.  KemPharm is actively seeking a strategic development partner with the expertise to take KP201 through regulatory review and commercialization.

About KemPharm
KemPharm is focused on the discovery and development of NCEs to treat serious medical conditions through its proprietary and broadly applicable LAT prodrug approach.  KemPharm utilizes its LAT prodrug technology to generate improved versions of FDA approved drugs.  KemPharm's business strategy includes seeking strategic development partners following rapid clinical proof-of-concept demonstration in a Phase 1 trial.  KemPharm also plans to explore discovery stage alliances with industry leaders, leveraging its prodrug know-how and LAT technology.  KemPharm is primarily focused on developing candidates for pain and other central nervous system disorders.

 For KemPharm, Inc:Media / Investor Contacts:Christal Mickle

Jason Rando / Claire Sojda319-665-2575

Tiberend Strategic Advisors,



SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. National Patient Advocate Foundation Supports 340B Drug Discount Program Review Identifying Risks to Underinsured Patients
2. Varian Medical Systems Supports Program to Tap Brain Power of Research and Development Community in Russia
3. Ameritox Leadership Supports Lawmakers, Pain Practitioners and Patients Confronting Crisis in Pain Medication Abuse
4. US Patent Granted to RBC Life Sciences for Supplement that Supports Cognitive Function
5. Amgen Backs States Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety
6. Novo Nordisk Supports Four San Francisco-based Organizations In Fight Against Diabetes
7. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
8. H. D. Smith Supports Local Hospitals, Nursing Homes, Clinics And Independent Retail Pharmacies Throughout Hurricane Sandy
9. Reproductive Medicine Associates of New York supports the ASRM endorsement of Oocyte Cryopreservation
10. Amgen Supports Assistance for Patients Affected by Hurricane Sandy
11. With Special Edition "Think Pink" Hearing Aids, The Atlanta Hearing Doctor Supports Breast Cancer Research and Better Hearing
Post Your Comments:
(Date:11/26/2015)... , November 27, 2015 /PRNewswire/ ... --> Medical ... response system (PERS) market is ... 5 years with APAC being ... to see a high CAGR ...
(Date:11/26/2015)... November 26, 2015 --> ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... has found that immunotherapy can be efficiently combined with ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... World Patent Marketing , a vertically ... invention that provides an economical and easy way of gaining customized curtains. , ... 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "There ...
(Date:11/29/2015)... (PRWEB) , ... November 30, 2015 , ... ... today from the new company, Sublime Beauty NATURALS®. All products are available on ... products, like essential oils, organic facial serums and USDA Certified Organic Sesame Oil ...
(Date:11/29/2015)... ... , ... The Cyber Monday deal is a deep 40% or more discount on every item ... for the skin care lover in your circle. Each Christmas, Sublime Beauty offers a ... 3 serums are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking stuffers like Skin Brushes, ...
(Date:11/29/2015)... ... November 29, 2015 , ... While conventional walkers afford considerable help ... access to exercise weights. Fortunately, an inventor from Uniontown, Pa., has found a way ... enhance the benefits of a standard walker to improve the user’s quality of life. ...
(Date:11/29/2015)... IL (PRWEB) , ... November 29, 2015 , ... Effective ... In addition starting on Black Friday Target is offering a “Buy One ... This is a rare opportunity to purchase IguanaMed at a discounted price. ...
Breaking Medicine News(10 mins):